Back to search results

LIVEBETTER: Comparing Medications for Stable Angina in Older Adults

This study, called LIVEBETTER, is looking at how well two common types of heart medications, beta blockers and calcium channel blockers, work in older adults. These adults have stable angina (chest pain due to heart disease) and also have at least two other ongoing health conditions. The study aims to understand which of these medications is more effective at improving your symptoms, daily function, and overall quality of life. It will also compare how well people tolerate each medication and their safety. You may be able to join if you are 65 or older, have stable ischemic heart disease (a type of heart disease where blood flow to the heart is reduced), and have multiple chronic conditions. The study plans to enroll 741 participants, but its current status is unclear.

Study design
This is a single-blind, randomized study comparing beta blocker therapy versus calcium channel blocker therapy. About 741 participants will be randomly assigned to one of the two treatment groups.
What's involved
You would have 4 study visits over a 12-month period. These visits include an interview, a six-minute walk test, and a review of your medical records.
Compensation
Not stated in the trial record.
Follow-up
Your quality of life will be assessed at the beginning of the study and again after 45 days. The study involves a 12-month follow-up period with four visits.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05786417

LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions

Recruiting
PHASE4Ages 65+InterventionalSupportive care
Yale University
~741 participants
Updated 2026-04-07 on ClinicalTrials.gov
What's tested:Clinician DiscretionBeta blockerCalcium channel blocker

At a glance

Recruiting sites
8 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Quality of Life assessed using EQ-5D-5L
Measured over Baseline and 45 days

Conditions

Angina
Stable Ischemic Heart Disease

Explore related trials

AnginaSubacute ischemic heart disease

Where it's being run

10 sites across 8 states
New York3
Connecticut1
Georgia1
Illinois1
Massachusetts1
North Carolina1
Ohio1
Virginia1

Study leadership

  • Michael Nanna, MD · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Michael Nanna, MD
[email protected]
(888) 683-0865
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥65 years
≥ 2 Multiple Chronic Conditions as defined by Centers for Medicare and Medicaid Services (CMS)
Diagnosis of Symptomatic Stable Ischemic Heart Disease with plans to initiate medical therapy identified by at least one of the following:
Age ≥ 18 years
Identified as caregiver of LIVEBETTER participant

Exclusion

Current taking (both) a beta-blocker AND a calcium channel blocker\*
Contraindication to beta-blockers or calcium channel blockers including:
Documented intolerance to beta-blockers or calcium channel blockers
Probable or definite high-risk coronary artery disease including unrevascularized left main disease and/or unrevascularized multi-vessel disease including the proximal left anterior descending (LAD) artery with plans for immediate complete revascularization
Plans for complete revascularization within 2 weeks
Clear clinical indication for beta-blockers or calcium channel blockers that precludes dose adjustment or crossover:
Actively participating in another clinical trial involving an investigational medication or device
Primary language other than English or Spanish
Inability to complete follow-up (e.g. life expectancy \<12 months, impaired decision-making determined by validated instrument)
Previously enrolled in LIVEBETTER
Refused informed consent
Professional caregiver (i.e. not a relative or close friend of the participant)
Primary language other than English or Spanish
Inability to complete follow-up
Previously enrolled in LIVEBETTER
Refused informed consent

What this trial measures

  • Change in Quality of Life assessed using EQ-5D-5LBaseline and 45 days

    The EQ-5D-5L represents a global quality of life measure that includes multiple components potentially impacted by the anti-anginal treatments being examined. The EQ-5D-5L score includes questions on mobility, self-care, usual activities, anxiety/depression, and pain/discomfort on a 5-point scale: 1=No Problem, 2=Slight Problem, 3=Moderate Problem, 4=Severe Problem, 5=Extreme Problem or Inability. 0, 1, and negative values corresponding to death, full health, and health states worse than death, respectively. Higher scores indicated greater levels of problems across each of the five dimensions.